Worldwide differences in regulations of clozapine use

CNS Drugs

Volumn 30, Issue 2, 2016, Pages 149-161

  Nielsen, Jimmi ^a,b   Young, Corina ^c   Ifteni, Petru ^d   Kishimoto, Taishiro ^e   Xiang, Yu Tao ^f   Schulte, Peter F J ^g   Correll, Christoph U ^h   Taylor, David ⁱ  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^d TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^e KEIO UNIVERSITY   (Japan)

^f University of Macau   (Macao)

^g Treatment Centre for Bipolar Disorders   (Netherlands)

^h ZUCKER HILLSIDE HOSPITAL   (United States)

ⁱ SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GENERIC DRUG; NEUROLEPTIC AGENT;

CHINA; DENMARK; DRUG CONTROL; GENERAL PRACTITIONER; HEMATOLOGICAL PARAMETERS; HUMAN; IRELAND; JAPAN; MONITORING; NETHERLANDS; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SUSPENSION; TABLET; UNITED KINGDOM; UNITED STATES; BLOOD; DRUG MONITORING; DRUG RESISTANCE; INTERNATIONAL COOPERATION; METABOLISM; PROCEDURES; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG AND NARCOTIC CONTROL; DRUG MONITORING; DRUG RESISTANCE; DRUGS, GENERIC; HUMANS; INTERNATIONALITY; SCHIZOPHRENIA;

EID: 84959893294     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0311-1     Document Type: Review

References (50)

1. Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999;60(Suppl 12):22-3.
2. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand. 1977;56(4):241-8.
3. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3-7.
4. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96.
5. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 2004;177(1-2):207-16.
6. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry. 2005;162(10):1984-5.
7. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004;161(9):1620-5.
8. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286-93.
9. Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 1997;338(2):R3-5.
10. Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1-3):204-13.
11. Veerman SR, Schulte PF, de Haan L. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. 2014;47(4-5):121-30.
12. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23(6):668-71.
13. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42(7):607-18.
14. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012;32(5):678-83.
15. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry. 1997;171:125-30.
16. Malalagama G, Bastiampillai T, Dhillon R. Clozapine use in Australia. Australas Psychiatry. 2011;19(2):175.
17. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.
18. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622-9.
19. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord. 2012;14(8):863-9.
20. Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168-72.
21. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-10.
22. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19(7):831-3.
23. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):603-13 (quiz 13).
24. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
25. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-78.
26. Netherlands Clozapine Collaboration Group. Dutch guideline for the use of clozapine. http://www.clozapinepluswerkgroep.nl/wp-content/uploads/2013/07/Guideline-for-the-use-of-Clozapine-2013.pdf. Accessed 6 Jun 2015.
27. NICE. National Health and Care Excellence schizophrenia guideline. 2015. http://pathways.nice.org.uk/pathways/psychosis-and-schizophrenia. Accessed 6 Jun 2015.
28. Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. Compulsory treatment with clozapine: a retrospective long-term cohort study. Int J Law Psychiatry. 2007;30(6):539-45.
29. Andersen TH, Kappers D, Sneider B, Uggerby P, Nielsen J. Involuntary treatment of schizophrenia patients 2004-2010 in Denmark. Acta Psychiatr Scand. 2014;129(4):312-9.
30. Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20(3):163-8.
31. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965-71.
32. Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer EP, Flanagan RJ. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol. 2009;23(2):206-10.
33. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123(6):411-22.
34. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
35. Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol. 2012;22(11):818-24.
36. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481-5.
37. Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract. 2009;15(3):441-50.
38. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand. 2014;130(1):16-24.
39. Nielsen J, Thode D, Stenager E, Andersen KO, Sondrup U, Hansen TN, et al. Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial. Eur Neuropsychopharmacol. 2012;22(6):401-5.
40. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging. 2008;25(8):665-82.
41. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47(10):945-8.
42. Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.
43. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25-35.
44. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458-65.
45. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132(4):231-40.
46. Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand. 2015;132(4):240-1.
47. Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307-12.
48. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust. 2009;190(4):190-2.
49. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759-68.
50. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophrenia Bull. 2012;38(3):592-8.